These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 24267474)

  • 1. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.
    Terdiman JP; Gruss CB; Heidelbaugh JJ; Sultan S; Falck-Ytter YT;
    Gastroenterology; 2013 Dec; 145(6):1459-63. PubMed ID: 24267474
    [No Abstract]   [Full Text] [Related]  

  • 2. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.
    Dassopoulos T; Sultan S; Falck-Ytter YT; Inadomi JM; Hanauer SB
    Gastroenterology; 2013 Dec; 145(6):1464-78.e1-5. PubMed ID: 24267475
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic role of methotrexate in pediatric Crohn's disease.
    Djurić Z; Šaranac L; Budić I; Pavlović V; Djordjević J
    Bosn J Basic Med Sci; 2018 Aug; 18(3):211-216. PubMed ID: 29338679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective.
    Axelrad JE; Roy A; Lawlor G; Korelitz B; Lichtiger S
    World J Gastroenterol; 2016 Dec; 22(46):10103-10117. PubMed ID: 28028358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate for Crohn's disease.
    Korelitz BI; Present DH
    N Engl J Med; 1995 Aug; 333(9):600-1. PubMed ID: 7623920
    [No Abstract]   [Full Text] [Related]  

  • 6. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.
    Panaccione R; Steinhart AH; Bressler B; Khanna R; Marshall JK; Targownik L; Afif W; Bitton A; Borgaonkar M; Chauhan U; Halloran B; Jones J; Kennedy E; Leontiadis GI; Loftus EV; Meddings J; Moayyedi P; Murthy S; Plamondon S; Rosenfeld G; Schwartz D; Seow CH; Williams C; Bernstein CN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1680-1713. PubMed ID: 30853616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The debated role for thiopurines in Crohn's disease.
    Herrlinger KR; Stange EF
    J Crohns Colitis; 2014 Feb; 8(2):172-4. PubMed ID: 24342765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
    Markowitz J; Grancher K; Mandel F; Daum F
    Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of medical therapy in preventing the post-surgical recurrence in Crohn's disease].
    Ardizzone S; Bollani S; Manzionna G; Colombo E; Maconi G; Imbesi V; Bianchi Porro G
    Ann Ital Chir; 2003; 74(6):621-5. PubMed ID: 15206802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How effective are the usual treatments for Crohn's disease?
    Bebb JR; Scott BB
    Aliment Pharmacol Ther; 2004 Jul; 20(2):151-9. PubMed ID: 15233694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: chronic active disease and maintaining remission in Crohn's disease.
    Kamm MA
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():102-5. PubMed ID: 15352904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate: the best choice for second-line maintenance treatment in active Crohn's disease?
    Grimaldi C
    Gastroenterol Clin Biol; 2009 Jan; 33(1 Pt 1):21-2. PubMed ID: 18977624
    [No Abstract]   [Full Text] [Related]  

  • 15. [Which place for methotrexate in treatment of luminal Crohn's disease?].
    Carbonnel F
    Gastroenterol Clin Biol; 2009 Jan; 33(1 Pt 1):18-20. PubMed ID: 19084362
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug resistance in inflammatory bowel diseases.
    Moreau J; Mas E
    Curr Opin Pharmacol; 2015 Dec; 25():56-61. PubMed ID: 26645664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive drugs in Crohn's disease.
    Kornbluth A; George J; Sachar DB
    Gastroenterologist; 1994 Sep; 2(3):239-46. PubMed ID: 7987622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-center experience with methotrexate after thiopurine therapy in pediatric Crohn disease.
    Boyle B; Mackner L; Ross C; Moses J; Kumar S; Crandall W
    J Pediatr Gastroenterol Nutr; 2010 Dec; 51(6):714-7. PubMed ID: 20706154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues.
    Weiss B; Lerner A; Shapiro R; Broide E; Levine A; Fradkin A; Bujanover Y
    J Pediatr Gastroenterol Nutr; 2009 May; 48(5):526-30. PubMed ID: 19412004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.